PTX 3.70% 3.9¢ prescient therapeutics limited

Gilead’s Kite Pharma gets FDA nod for second CAR-T cell...

  1. 4,311 Posts.
    lightbulb Created with Sketch. 2015

    Gilead’s Kite Pharma gets FDA nod for second CAR-T cell therapy

    The agency approved Tecartus, previously developed under the name KTE-X19, as the first CAR-T therapy for mantle cell lymphoma. The company had previously won approval for another CAR-T, Yescarta. Tecartus is a similar product, but with a different manufacturing process.

    One of the first companies to win Food and Drug Administration approval for a CAR-T cell therapy has received the agency’s nod for its second product.

    Kite Pharma, a subsidiary of Foster City, California-based Gilead Sciences, said Friday that the FDA had given accelerated approval to Tecartus (brexucabtagene autoleucel) as the first CAR-T cell therapy approved for mantle cell lymphoma, an indolent – or slow-growing – form of non-Hodgkin’s lymphoma. Kite had previously received approval for its first CAR-T, Yescarta (axicabtagene ciloleucel), for diffuse large B-cell lymphoma; Tecartus is a similar product to Yescarta and targets the same antigen, CD19, but uses a different manufacturing process, hence the different branding.



    This Car-T is still in its infancy. It would be good if they have found a better way for using it.
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
3.9¢
Change
-0.002(3.70%)
Mkt cap ! $31.40M
Open High Low Value Volume
4.0¢ 4.0¢ 3.9¢ $31.53K 794.9K

Buyers (Bids)

No. Vol. Price($)
8 456872 3.9¢
 

Sellers (Offers)

Price($) Vol. No.
4.1¢ 66952 1
View Market Depth
Last trade - 15.43pm 24/06/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.